Big Data is Bringing New Capabilities to Drug Discovery and...
pharmatechoutlook

Big Data is Bringing New Capabilities to Drug Discovery and Development!

By Pharma Tech Outlook | Friday, August 23, 2019

The new capabilities facilitated by big data and predictive analytics are enabling pharmaceutical companies to develop safe and effective drugs while also maintaining cost-effectiveness.

FREMONT, CA – The evolution of big data is creating waves in the pharmaceutical sector, especially in the drug discovery and development segment. The incorporation of predictive analytics shows excellent potential in forecasting the demand in the market. With over 45 percent of the global market share, the pharmaceutical industry is one of the largest in the world. The emergence of big data is enabling pharma organizations to save billions of dollars by bolstering their decisions with robust analytics.

The application of big data strategies has empowered pharma enterprises to enhance their capabilities. The estimates show that it could lead to the generation of over $100 billion in value in the US alone. With the incorporation of big data, organizations have bolstered innovation and optimized efficiency in pharmaceutical research and clinical trials. Using insights from big data, providers are developing customized tools for physicians, clinicians, insurers, and regulators.

The pharmaceutical industry has witnessed an explosive inflow of data from a multitude of sources, including drug discovery & development, retailers, patients, and caregivers. Organizations are leveraging robust artificial intelligence-based automation systems to harness the data and generate valuable insights. It has not only enabled them to identify potential drug candidates and develop effective medicines in the shortest period.

Check This Out: Top Drug Discovery and Development Companies

The liability factors in the pharma sector are most prevalent in the research and development process. Often, organizations rush the development process and release the drugs into the market without conducting sufficient trials, and this can often result in massive lawsuits. To prevent this, it is advisable for organizations to utilize big data.

Big data is led to the inception of predictive modeling, which uses clinical and molecular data to inform the development of safe and effective drugs. By utilizing big data-based selection procedure for clinical patients, organizations are optimizing the clinical trials. It has enabled them to target patients with specific genetic makeup, thus facilitating smaller sample sizes, enhanced success rates, and lesser expense.

Predictive modeling of drugs and biological processes is a sophisticated process which leverages diverse datasets of molecular and clinical data, helping researchers to identify potential candidate molecules which can effectively act on the biological targets. By monitoring the trials in real-time, organizations can track the operational factors and take prompt action whenever required to avert any adversities later on.

The seamless flow of data between various function, including discovery and development, physicians, contract research organizations (CROs), and so on, have enabled real-time predictive analytics and generation of business value. The monitoring capabilities have led to quicker safety measures, fewer delays, and faster responses.

The real-time analysis can significantly increase the success rate for research and development processes, with better outcomes for trial participants. The access to vast troves of health data has enabled pharma organizations to better understand the effect of medicine in real-time. The collaboration of pharma companies and tech enterprises has led to the utilization of big data capabilities to resolve issues and facilitate higher value for drugs.

Clinical trials are significantly less effective if isolated from real-time information such as medical records, insurance claims, and social media, which can assist researchers in connecting drugs to new markets. It will enable them to identify and predict the outcomes of different medicines on the patients. It has spurred major pharma industries to form separate departments to gather and analyze data across various diseases and inform the decisions on drug development.

Big data technology is enabling organizations to combat the high expenses of conventional clinical trials, and at the same time developing more potent and effective drugs. Although many pharma organizations have hesitated to invest in enhancing their big data capabilities, they are waking up to its advantages. The opportunities offered by big data are vast and significant, and there is little doubt regarding its crucial role in boosting clinical success rate.

Key Drug Discovery and Development Companies:  Lixoft, Mcule, NTxBio

Weekly Brief

New Editions